Issue link: https://uberflip.scri.com/i/1521059
Vivek Subbiah, MD, Joined SCRI to Advance Early-Phase Clinical Research In May 2023, SCRI announced that Dr. Vivek Subbiah had joined the organization as Chief of Early-Phase Drug Development. In his role, Dr. Subbiah oversees SCRI's eight drug development units and leads the expansion of early- phase capabilities and programs across the organization's growing research network. Dr. Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in- human and practice-changing studies that directly led to approvals from the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and other agencies across the world. Furthermore, he has an exceptional track record of effectively bringing together multidisciplinary clinical trials teams, early career physician investigators, and physicians in training, all with the shared commitment to bringing novel therapies to patients with cancer. Having trained in both pediatric hematology & oncology as well as adult medical oncology, Dr. Subbiah is uniquely positioned to bring cutting- edge therapeutics across the age continuum from adolescent/young adults (AYAs) to older adults with cancer.